MediGene Receives Further European Patent on EndoTAG-1
Patent renews coverage and expands the protected territory
Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "This new patent is extremely important for MediGene and for the commercialization of EndoTAG(TM)-1. In addition to the good patent protection which we already possess for the EndoTAG(TM) technology in general and for EndoTAG(TM)-1 in particular, the manufacturing process and the dried formulation of our drug candidate are now also patented. Overall patent protection is renewed for the product in itself, and the protected territory has been enlarged by a number of European countries. Whereas EndoTAG(TM)-1 is administered in the form of a suspension, the drug will be commercialized in the form of a dried product, so the patent represents a major progress toward our future plans for commercialization."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.